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ABSTRACT
Introduction. Insulin therapy plays an important role in 
the management of diabetes mellitus. The primary goal 
of insulin therapy is to achieve the best possible glycemic 
control without hypoglycemia. First-generation basal 
insulin (BI) analogues, such as insulin glargine 100 U/ml 
(Gla-100) and insulin detemir (IDet), provide more 
prolonged and stable activity than neutral protamine 
Hagedorn (NPH) insulin, with a lower risk of hypogly-
cemia. Insulin glargine 300 U/mL (glargine U 300) is 
a long acting basal insulin analogue approved for the 
treatment of diabetes mellitus. Insulin glargine 300 U/mL 
has a more stable and prolonged pharmacokinetic/ 
/pharmacodynamics profile than insulin glargine 
100 U/mL, with a duration of glucose-lowering activ-
ity exceeding 24 h. Although the average daily insulin 
dose was higher, hypoglycemia episodes were lower 
in patients treated with Gla-300 compared with those 
treated with Gla-100. This is due to a more extended 
time action profile than Gla-100 resulting in a more 
stable and sustained glycemic control. The formula-
tion of Gla-100 delivers the same amount of Insulin 
as Gla-300, in a third of the injection volume. It is es-
sential to determine whether the clinical benefits of 
hypoglycemia reduction observed with insulin glargine 
in RCTs translate into a real-life clinical practice setting.
Materials and methods. Fifty patients diagnosed with 
type 2 diabetes mellitus with uncontrolled plasma 
glucose levels (HbA1c of > 7.5) who were on oral 
hypoglycemic agents, premix insulin and basal bolus 
therapy were enrolled into the study and started on 
glargine U 300 at a dose of 0.2 IU/kg and analysed for 
glycemic and kidney function parameters. The patients 
were followed up at 3 and 6 months post treatment.
Results. All glycemic control parameters decreased 
significantly with almost a 50% decline in both FBS and 
PBS from baseline to 6 months. The HbA1c decreased 
significantly from baseline to 3 months and 6 months 
post treatment by 18% and 29% respectively. All 
biochemical parameters were found to be statistically 
significant in both groups.
Conclusions. In patients with uncontrolled type 2 dia-
betes, switching from either OHAs or insulin to Gla-300 
improves glycemic control, with a low incidence of 
hypoglycemia. These results confirm the effectiveness 
and safety of Gla-300 in a real-world setting and show 
that Gla-300 is a suitable therapy option for patients 
with diabetes. (Clin Diabetol 2020; 9)
Key words: type 2 diabetes mellitus, insulin 
analogues, glargine U 300, hypoglycemia, kidney 
function parameters, HbA1c, fasting blood sugar, 
post prandial blood sugar
Introduction
Diabetes mellitus is a metabolic disease marked by 
elevated plasma glucose. In type 2 diabetes mellitus 
(T2DM), the pancreas often continues to produce 
insulin, sometimes even at higher-than-normal levels, 
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especially early in the course of the disease. However, 
the body develops resistance to the effects of insulin, 
so there is not enough insulin to meet the body’s 
needs. As type 2 diabetes progresses, the insulin-
-producing ability of the pancreas decreases. T2DM 
tends to develop in adults, and it results from insulin 
resistance accompanied by a gradual decline in b-cell 
function. In T1 and T2DM, impaired glucose regulation 
leads to chronic hyperglycemia, which induces a variety 
of vascular complications.
The global diabetes epidemic has reached alarming 
proportions, particularly in Asia. In 2017, prevalence 
among adults ranged from 7.7% to 13.7% in this region 
with more than 1 million diabetes-related deaths [1].
Although there is no cure for diabetes yet, it can be 
treated and effectively controlled. The goals of diabetes 
management are to keep the plasma glucose levels as 
near to optimal levels as possible by balancing diet with 
medication and activity. Other co-morbidities such as 
hypercholesteremia, hypertension and dyslipidemia 
should also be controlled. Despite the introduction 
of numerous anti-hyperglycemic medications, many 
patients with T2DM require insulin, and basal insulins 
continue to be frequently used either as first-line in-
sulin treatment or as part of multiple daily injection 
regimens. Current American Diabetes Association (ADA) 
guidelines recommend a HbA1c target of 7.0% [2].
Insulin therapy plays an important role in the man-
agement of diabetes mellitus. The primary goal of insulin 
therapy is to achieve the best possible glycemic control 
without hypoglycemia. First-generation basal insulin (BI) 
analogues, such as insulin glargine 100 U/ml (Gla-100) 
and insulin detemir (IDet), provide more prolonged 
and stable activity than neutral protamine Hagedorn 
(NPH) insulin, with a lower risk of hypoglycemia [3]. It 
is essential to determine whether the clinical benefits of 
hypoglycemia reduction observed with insulin glargine 
in RCTs translate into a real-life clinical practice setting.
Insulin glargine 300 U/mL (glargine U 300) is 
a long acting basal insulin analogue approved for the 
treatment of diabetes mellitus. Insulin glargine 300 U/mL 
has a more stable and prolonged pharmacokinetic/ 
/pharmacodynamics profile than insulin glargine 
100 U/mL, with a duration of glucose-lowering activity 
exceeding 24 h. Clinical trial data has shown that, fol-
lowing injection, Gla-300 has slower rate of release into 
the surrounding tissues when compared with Gla-100. 
This results in a more even plasma concentration of the 
drug and also better glucose lowering effect resulting 
in a longer duration of action that fully covers a 24-h 
dose period with a single injection [4].
The efficacy and safety of Gla-300 was studied 
extensively in the EDITION series of clinical trials, which 
compared Gla-300 with Gla-100 in patients with T1D 
or T2D, with differing treatment backgrounds. These 
clinical trials demonstrated that hemoglobin A1c level 
decreased by equivalent amounts with Gla-300 and 
Gla-100 treatment, regardless of the type of diabetes or 
whether patients were insulin naive or being switched 
from oral treatment with another basal insulin. 
The most common and serious adverse effect of 
insulin treatment, hypoglycemia remains a key unmet 
medical need in insulin-treated diabetes. Insulin re-
lated hypoglycemia and insulin-use errors account for 
a significant number of hospital visits. The risk of hypo-
glycemic episodes increase in the elderly and patients 
with renal impairment. Although the average daily 
insulin dose was higher, hypoglycemia episodes were 
lower in patients treated with Gla-300 compared with 
those treated with Gla-100 [5, 6]. This is due to a more 
extended time action profile than Gla-100 resulting 
in a more stable and sustained glycemic control. The 
formulation of Gla-100 delivers the same amount of 
Insulin as Gla-300, in a third of the injection volume.
The current study was envisaged to evaluate the 
effects of Gla-300 when prescribed in uncontrolled dia-
betes including to assess effects on markers of kidney 
function along with parameters determining glycemic 
control over a period of six months prompting the need 
for a more careful management of insulin therapy.
Materials and methods
This was an observational study. 50 patients diag-
nosed with type 2 diabetes mellitus with uncontrolled 
plasma glucose levels (HbA1c of > 7.5) who were on 
oral hypoglycemic agents  premix insulin or basal 
bolus regime, were enrolled into the study. Initially all 
subjects were started on glargine U 300 at a dose of 
0.2 IU/kg. Patients treated in diabetes clinic of Ruby 
General Hospital and principal investigator had com-
plete oversight of the patients during the six month 
study period. The dose was titrated up to 0.4 IU/kg over 
a period of two weeks according to self-monitoring 
for blood glucose (SMBG) diary. Patients who were on 
premix insulin were converted to basal bolus regime 
with the basal insulin being glargine U 300 and bolus 
insulin with human insulin Actrapid. In patients who 
were already on basal bolus insulin their basal insulin 
was changed to glargine U300, keeping bolus dose 
unaltered. Patients were instructed to do SMBG per 
day and maintain a diary. The 5 SMBGs recommended 
were 3 premeals, 1 bedtime and 1 at 3 am and SOS 
measurement if the subjects experienced an episode 
of hypoglycaemia. Hypoglycemia was defined as glu-
cose levels below 70 mg/dL. Patients were instructed 
to look out for symptoms suggestive of hypoglycemia 
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such as dizziness, excessive sweating, reeling of head, 
confusion. The target glucose levels were between 
140–180. Glargine U 300 was titrated to a target 
pre-prandial glucose concentration of 100–130 mg/dL 
and postprandial glucose concentration of 140– 
–180 mg/dL based on CBG levels assessed on a weekly 
basis for two weeks at the clinic. Patients with type 1 
diabetes, pregnant or lactating mothers, allergic to 
insulin or having estimated glomerular filtration rate 
(eGFR) of ≤ 30 were excluded. Demographic details, 
details of diabetes such as duration, treatment and 
diabetes education received etc. were collected from 
the patients. Two subjects were lost to follow up 
during the course of the study. One subject died due 
to bronchogenic carcinoma which was not related to 
insulin. The other subject dropped out because she 
could not afford the expenses involved in the therapy. 
The primary objective of the study was to evaluate 
the change in the parameters of fasting blood sugar, 
post prandial blood sugar and HBA1c from baseline to 
3 months and 6 months post treatment. The second-
ary objective was to evaluate the change in the para-
meters of biochemical markers of renal function from 
baseline to 3 months and 6 months post treatment. 
The safety objective was to evaluate the episodes of 
hypoglycaemia during the study period.
This study was carried out on FDA approved insulin 
analogue among Indian patients with diabetes. This 
study was conducted in accordance to the Declaration 
of Helsinki (1975 as revised in 2013).
Statistical analysis
All data analysis was carried out as per a com-
prehensive pre-planned statistical analysis plan. The 
intention-to treat analysis of the primary study end 
point was performed on all randomly allocated partici-
pants who satisfactorily complete all follow up visits. 
To evaluate the overall effects of glargine U 300 on 
markers of glycemic control and chronic kidney disease, 
the mean changes from baseline to 3 months and 
6 months post treatment is calculated. P-value 0.05 was 
defined as the level of statistical significance. Data is 
expressed as mean ± SD for continuous variables and 
as  percentage for categorical variables. 
Results
Table 1 summarizes the demographic characteristics 
of the patients. The average age of the subjects in the 
study was 58.42 ± 9.65 years. The average age of males 
were higher compared to the females (60.4 ± 10.79 vs. 
56.26 ± 7.92 years). The average height of subjects in 
the study was 162.94 ± 9.22 cm with males compara-
tively taller than females (166.84 ± 8.35 vs. 158.7 ± 
± 8.34 cm). The average weight of subjects in the study 
was 66.35 ± 11.67 kg with males comparatively heavier 
than females (69.76 ± 11.65 vs. 62.65 ± 10.74 kg). 
The average BMI of the subjects was 25.03 ± 3.99.
Table 2 summarizes the biochemical parameters 
(ACR, eGFR, FBS, PBS and HbA1c) for all enrolled pa-
tients compared from baseline to the third month and 
the sixth month using repeated measures ANOVA and 
Table 1. Demographics of the study population
All subjects (N = 48) Male (N = 25) Female (N = 23)
Age in years (mean) 58.42 ± 9.65 60.4 ± 10.79 56.26 ± 7.92
Height [cm] 162.94 ± 9.22 166.84 ± 8.35 158.7 ± 8.34
Weight [kg] 66.35 ± 11.67 69.76 ± 11.65 62.65 ± 10.74
BMI [kg/m2] 25.03 ± 3.99 25.19 ± 4.3 24.84 ± 3.73 
BMI — body mass index
Table 2. Comparison of changes in biochemical parameters in 48 subjects at baseline, 3 months and 6 months follow up
Age  
(N = 48)
BMI Gender Baseline 3 months 6 months Change in  
3 months (%)
Change in  
6 months (%)
P-value
58.42 ± 9.65 25.02 ± 4 ACR 46.5 ± 44.1 33.54 ± 27.82 24.31 ± 17.79 –27.87 –47.72 0.00003
eGFR 78.06 ± 13.54 81.33 ± 12.44 83.58 ± 12.36 4.19 7.07 < 0.00001
FBS 213.73 ± 71.92 138.75 ± 29.66 112.04 ± 25.25 –35.08 –47.58 < 0.00001
PPBS 345.46 ± 91.63 229.38 ± 49.25 178.73 ± 21.69 –33.60 –48.26 < 0.00001
HbA1c 10.03 ± 0.91 8.24 ± 0.67 7.1 ± 0.24 –17.88 –29.28 < 0.00001
BMI — body mass index; ACR — albumin creatinine ratio in spot urine sample; eGFR — estimated glomerular filtration rate by CKD-EPI formula; FBS — fast-
ing blood sugar; PPBS — 2 hour post prandial blood sugar
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were found to be statistically significant. There was 
a reduction of 27% and 47% in albumin creatinine ratio 
from baseline to 3 months and 6 months respectively. 
Similarly the eGFR increased by 4% and 7% from base-
line to 3 months and 6 months respectively. All glycemic 
control parameters decreased significantly with a 47% 
and 48% decline in FBS and PPBS from baseline to 
6 months respectively. The HbA1c decreased significantly 
from baseline to 3 months and 6 months post treat-
ment by 17% and 29% respectively.
Subjects were categorized into mildly increased and 
moderately increased groups based on the ACR values, 
assuming a cut of level of (< 30 mg/g) irrespective of 
their BMI status with 23 and 25 subjects respectively. All 
biochemical parameters were found to be statistically 
significant in both groups. Although there was an in-
crease of 46% in albumin creatinine ratio from baseline 
to 3 months the values decreased at 6 months. Similarly 
the eGFR increased by 5% and 9% from baseline to 
3 months and 6 months respectively. All glycemic 
control parameters decreased significantly with a 44% 
and 46% decline in both FBS and PBS from baseline 
to 6 months. The HbA1c decreased significantly from 
baseline to 3 months and 6 months post treatment by 
18% and 28% respectively (Table 3).
Biochemical parameters for ACR levels of moder-
ately increased groups irrespective of BMI status were 
evaluated. There were statistically significant differ-
ences in all parameters from baseline to 3 months and 
6 months (Table 4).
Biochemical parameters for overweight subjects 
according to the BMI were analyzed for ACR levels of 
moderately increased groups. Although there were 
statistically significant differences in all parameters 
from baseline to 3 months and 6 months, the eGFR 
in the moderately increased group was found to be 
statistically not significant (Table 5). 
Comparison of parameters in subjects receiving 
Insulin along with oral hypoglycemic agents (OHAs) is 
presented above. The biochemical parameter of ACR 
and eGFR along with glycemic parameters HbA1c and 
FBS and PBS reduced from baseline to study end and 
this reduction was statistically significant (Table 6). 
The number of subjects at various levels of intensity 
of risk for CKD were analyzed considering both eGFR 
and UACR values. It was found that there was a decline 
in the number of subjects in the moderately increased 
risk by the end of the study, whereas the number of 
subject in the low risk category increased from 21 to 
38 towards the end of 6 months of the study (Table 7).
Table 4. Baseline characteristics by categories of ACR (30–300 mg/g i.e., microalbuminuria) irrespective of BMI status and 
% change after treatment received
Age BMI Parameters 
N = 25
Baseline 3 months 6 months Change in  
3 months (%)
Change in  
6 months (%)
P-value
57.44 ± 9.28 25.64 ± 4.57 ACR 73.2 ± 47.19 40.88 ± 26.55 34.6 ± 19.25 –44.15 –52.73 < 0.00001
eGFR 80.64 ± 15.23 82.8 ± 14.46 84.72 ± 14 2.68 5.06 0.0006
FBS 222.28 ± 87.77 138.84 ± 25.63 110.28 ± 14.26 –37.54 –50.39 < 0.00001
PPBS 360.68 ± 95.76 231.48 ± 50.21 180.08 ± 15.28 –35.82 –50.07 < 0.00001
HbA1c 10.18 ± 1.1 8.44 ± 0.73 7.14 ± 0.28 –17.09 –29.86 < 0.00001
BMI — body mass index; ACR — albumin creatinine ratio in spot urine sample; eGFR — estimated glomerular filtration rate by CKD-EPI formula; FBS — fast-
ing blood sugar; PPBS — 2 hour post prandial blood sugar
Table 3. Baseline characteristics by categories of ACR (< 30 mg/g i.e., normal) irrespective of BMI status and % change 
after treatment received
Age BMI Parameters 
N = 23
Baseline 3 months 6 months Change in  
3 months (%)
Change in  
6 months (%)
P-value
59.48 ± 10.14 24.35 ± 3.24 ACR 17.48 ± 5.98 25.57 ± 27.51 13.13 ± 4.59 46.28 –24.89 0.0355
eGFR 75.26 ± 11.1 79.74 ± 9.88 82.35 ± 10.46 5.95 9.42 < 0.00001
FBS 204.43 ± 49.71 138.65 ± 34.10 113.96 ± 33.66 –32.18 –44.25 < 0.00001
PPBS 328.91 ± 85.93 227.09 ± 49.2 177.26 ± 27.32 –30.96 –46.11 < 0.00001
HbA1c 9.88 ± 0.64 8.02 ± 0.52 7.05 ± 0.18 –18.83 –28.64 < 0.00001
BMI — body mass index; ACR — albumin creatinine ratio in spot urine sample; eGFR — estimated glomerular filtration rate by CKD-EPI formula; FBS — fast-
ing blood sugar; PPBS — 2 hour post prandial blood sugar
Asis Mitra et al., Low dose glargine U 300 on uncontrolled type 2 diabetes mellitus
5
There were 5 (10%) patients who reported episodes 
of hypoglycaemia at various time points in the course 
of the study. None of the patients required hospitaliza-
tion and were managed with oral glucose solution. The 
dose of their OHA or insulin was reduced. 
Discussion
This observational study evaluated the efficacy and 
safety of glargine U 300 in patients with uncontrolled 
T2DM on oral hypoglycemic agents and/or insulin 
therapy. The subjects were switched to Gla-U 300 as 
they failed to respond to current line of management 
due to less than optimal glycemic control. The study 
aims to explore the effectiveness and safety of Gla-U 
300 in eastern Indian population. All patients were 
initially started on a low dose of 0.2 units as against 
the western standard of 0.4 units, the rationale behind 
this approach is the lower BMI observed in Indian 
population. After adequate titration the patients were 
followed up at 3 months and 6 months. Glycemic 
control was significantly improved with a very low 
incidence rate of hypoglycemia and no significant 
weight change.
The switch over from basal/bolus insulin or oral 
hypoglycemic agents to Gla-300 has been studied in 
previous trials. The EDITION-2, a phase 3a randomized 
controlled trial and DELIVER-2 was a retrospective 
cohort study that used propensity score matching. 
After 3 and 6 months of therapy with Gla-300, there 
was significant reductions in mean HbA1c by 17% and 
28% respectively in male patients and by 18% and 29% 
respectively in male patients.
Table 5. Baseline characteristics by categories of ACR (30–300 mg/g i.e., microalbuminuria) and BMI status of overweight 
and % change after treatment received
Age BMI Parameters 
N = 13
Baseline 3 months 6 months Change in  
3 months (%)
Change in  
6 months (%)
P-value
57.54 ± 9.97 27.92 ± 1.26 ACR 89.85 ± 57.36 50.62 ± 33.15 41.77 ± 20.7 –43.66 –53.51 0.0003
eGFR 84.92 ± 13.33 86.77 ± 12.13 88.77 ± 12.45 2.18 4.53 0.1128
FBS 192.23 ± 43.32 130 ± 19.85 105.85 ± 9.81 –32.37 –44.94 < 0.00001
PPBS 347.69 ± 52.57 222.08 ± 22.86 181.08 ± 11.82 –36.13 –47.92 < 0.00001
HbA1c 10.08 ± 0.46 8.43 ± 0.33 7.15 ± 0.2 –16.37 –29.07 < 0.00001
BMI — body mass index; ACR — albumin creatinine ratio in spot urine sample; eGFR — estimated glomerular filtration rate by CKD-EPI formula; FBS — fast-
ing blood sugar; PPBS — 2 hour post prandial blood sugar
Table 6. Comparison of biochemical parameters  in insulin (once daily glargine U 300) + oral hypoglycemic agents (OHAs) 
group at baseline, 3 months and 6 months follow up
Age BMI Parameters 
N = 43
Baseline 3 months 6 months Change in  
3 months (%)
Change in  
6 months (%)
P-value
58.42 ± 9.65 25.02 ± 4 ACR 46.5 ± 44.1 33.54 ± 27.82 24.31 ± 17.79 –27.87 –47.72 0.00003
eGFR 78.06 ± 13.54 81.33 ± 12.44 83.58 ± 12.36 4.19 7.07 < 0.00001
FBS 213.73 ± 71.92 138.75 ± 29.66 112.04 ± 25.25 –35.08 –47.58 < 0.00001
PPBS 345.46 ± 91.63 229.38 ± 49.25 178.73 ± 21.69 –33.60 –48.26 < 0.00001
HbA1c 10.03 ± 0.91 8.24 ± 0.67 7.1 ± 0.24 –17.88 –29.28 < 0.00001
BMI — body mass index; ACR — albumin creatinine ratio in spot urine sample; eGFR — estimated glomerular filtration rate by CKD-EPI formula; FBS — fast-
ing blood sugar; PPBS — 2 hour post prandial blood sugar
Table 7. Comparison of no of subjects in term of risk at baseline, 3 months and 6 months follow up [7]
Intensity of risk Baseline 3 Months 6 months
Low risk 21 (43.75%) 28 (58.33%) 38 (79.17%)
Moderately increased risk 27 (56.25%) 20 (41.67%) 10 (20.83%)
High risk 0 0 0
Very high risk 0 0 0
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Biochemical parameters (ACR, eGFR, FBS, PBS and 
HbA1c) from baseline to 3 months and 6 months post 
treatment were assessed using repeated measures of 
ANOVA and were found to be statistically significant. 
There was a reduction of 27% and 47% in albumin cre-
atinine ratio from baseline to 3 months and 6 months 
respectively. Similarly the eGFR increased by 4% and 7% 
from baseline to 3 months and 6 months respectively. 
All glycemic control parameters decreased significantly 
with a 47% and 48% decline in FBS and PPBS from 
baseline to 6 months respectively. The HbA1c decreased 
significantly from baseline to 3 months and 6 months 
post treatment by 17% and 29% respectively.
The majority of the patients i.e. 25(50%) achieved 
their individual HbA1c target of 7% by switching their 
basal insulin to Gla-300, while 24 (48%) achieved HbA1c 
level of below 7.5%. 
Adequate dose titration is essential after the initia-
tion of an insulin regimen after careful evaluation of the 
patient’s glycemic control, but maybe delayed in clini-
cal practice resulting in prolongation of the duration 
of diabetes and other comorbidities. Most important 
barrier for dose titration are concerns about hypogly-
cemia. First-generation basal insulin analogues such as 
Gla-100 were shown to provide significant advantages 
over NPH insulin regarding the risk for hypoglycemic 
events and administration, and recently approved 
second-generation basal insulins such as Gla-300 afford 
even greater improvements. This was illustrated in our 
study wherein a good number of patients were still 
maintained on the low dose of 0.2–0.3 IU/kg (89.5%) 
and only 5 subjects required a dose titration to 0.4 units 
(10%). The number of hypoglycaemia episodes were 
also not significant with only 5 subjects (10.4%) re-
porting events none of which required hospitalization.
A major limitation of the current study was the 
small number of patients (n = 50) that were followed 
up until 6 months. The lack of a direct comparator is 
another major limitation, as no information on the 
outcomes with alternative lines of treatment could be 
compared. However, the study demonstrated consist-
ent and sustained glucose control with Gla-300 and 
a significantly lower risk of hypoglycemia. 
Conclusion
In patients with uncontrolled type 2 diabetes, 
switching from either OHAs or insulin to Gla-300 
improves glycemic control, with a low incidence of 
hypoglycemia. These results confirm the effectiveness 
and safety of Gla-300 in a real-world setting and show 
that Gla-300 is a suitable basal insulin therapy option 
for patients with type 2 diabetes mellitus.
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